Scholarlink

Background <p>Acute kidney injury (AKI) is a clinically significant complication after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Although multiple renal protective strategies have been proposed, the role of intraoperative urine output during the hyperthermic phase remains unclear. This study aimed to identify risk factors for postoperative AKI in a large CRS-HIPEC cohort and evaluate the impact of urine output during heated perfusion.</p> Methods <p>A retrospective cohort study analyzed 512 patients who underwent CRS-HIPEC between January 2011 and September 2022. Patient characteristics and perioperative variables including intra-HIPEC urine output, chemotherapy regimens, and postoperative complications were collected. The study defined AKI using Kidney Disease Improving Global Outcomes (KDIGO) criteria. Multivariate logistic regression identified independent predictors of postoperative AKI, and receiver operating characteristic (ROC) analysis determined optimal urine output thresholds.</p> Results <p>The overall incidence of AKI was 14 %, increasing to 23 % among patients receiving cisplatin-based HIPEC. Lower intra-HIPEC urine output was independently associated with AKI irrespective of total fluid volume and cisplatin exposure. A threshold of ≤11 mL/kg/h was identified as the optimal urine output cutoff for predicting AKI (odds ratio, 3.36; 95 % confidence interval, 1.68–6.71; <i>p</i> = 0.001). Additional independent predictors of AKI included peritoneal carcinomatosis index of ≥20, prolonged operative time, and low postoperative albumin (≤2.5 g/dL).</p> Conclusions <p>High urine output during the HIPEC phase of treatment was associated with reduced AKI risk across chemotherapy regimens, supporting targeted diuresis as a complementary renal protection strategy alongside sodium thiosulfate in cisplatin-based HIPEC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Protective Effect of Diuresis During Hyperthermia on Acute Kidney Injury in Cytoreductive Surgery with HIPEC

  • 期刊论文

  • 发表日期：

    2026年3月25日

查看全文
  • Julia Nieto-Elizalde,
  • Matilde Zaballos,
  • María Iluminada Canal,
  • Eneko Cabezuelo Markaide,
  • Mercedes Power Esteban,
  • Pilar Cabrerizo,
  • María Dolores Ginel Feito,
  • Mar Establés Learte,
  • Pablo Lozano Lominchar,
  • Luis González Bayón

摘要

Background

Acute kidney injury (AKI) is a clinically significant complication after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Although multiple renal protective strategies have been proposed, the role of intraoperative urine output during the hyperthermic phase remains unclear. This study aimed to identify risk factors for postoperative AKI in a large CRS-HIPEC cohort and evaluate the impact of urine output during heated perfusion.

Methods

A retrospective cohort study analyzed 512 patients who underwent CRS-HIPEC between January 2011 and September 2022. Patient characteristics and perioperative variables including intra-HIPEC urine output, chemotherapy regimens, and postoperative complications were collected. The study defined AKI using Kidney Disease Improving Global Outcomes (KDIGO) criteria. Multivariate logistic regression identified independent predictors of postoperative AKI, and receiver operating characteristic (ROC) analysis determined optimal urine output thresholds.

Results

The overall incidence of AKI was 14 %, increasing to 23 % among patients receiving cisplatin-based HIPEC. Lower intra-HIPEC urine output was independently associated with AKI irrespective of total fluid volume and cisplatin exposure. A threshold of ≤11 mL/kg/h was identified as the optimal urine output cutoff for predicting AKI (odds ratio, 3.36; 95 % confidence interval, 1.68–6.71; p = 0.001). Additional independent predictors of AKI included peritoneal carcinomatosis index of ≥20, prolonged operative time, and low postoperative albumin (≤2.5 g/dL).

Conclusions

High urine output during the HIPEC phase of treatment was associated with reduced AKI risk across chemotherapy regimens, supporting targeted diuresis as a complementary renal protection strategy alongside sodium thiosulfate in cisplatin-based HIPEC.